Allen Barbieri Purchases 20,000 Shares of Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc. (NASDAQ:BMRA) Vice Chairman Allen Barbieri bought 20,000 shares of Biomerica stock in a transaction dated Wednesday, August 26th. The stock was purchased at an average cost of $1.60 per share, with a total value of $32,000.00. Following the completion of the acquisition, the insider directly owned 73,542 shares in the company, valued at approximately $117,667.20. The trade was a 37.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Biomerica Stock Up 1.9%

Shares of NASDAQ BMRA opened at $2.14 on Friday. The business has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.99. The stock has a market cap of $6.61 million, a PE ratio of -2.40 and a beta of 0.35. Biomerica, Inc. has a 52-week low of $1.45 and a 52-week high of $3.22.

Analyst Ratings Changes

BMRA has been the subject of several research reports. Weiss Ratings downgraded shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 5th. Citizens Jmp began coverage on Biomerica in a research report on Tuesday, May 5th. They issued a “mkt outperform” rating and a $9.00 price target on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell” and a consensus target price of $9.00.

Institutional Trading of Biomerica

A hedge fund recently bought a new stake in Biomerica stock. BlackRock Inc. purchased a new position in shares of Biomerica, Inc. (NASDAQ:BMRA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,636 shares of the company’s stock, valued at approximately $33,000. BlackRock Inc. owned 0.60% of Biomerica as of its most recent SEC filing. Institutional investors own 22.28% of the company’s stock.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.